Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vision-Sciences digital endoscopes:

This article was originally published in Clinica

Executive Summary

Vision-Sciences has received 510(k) clearance from the US FDA for two of its advanced digital endoscopes, which the firm claims are "poised to replace prevalent old fibre-optic technology". The video-based endoscopes - one for ear, nose and throat (ENT) assessment, and the other for transnasal oesophagoscopy (TNO) - come with a built-in light source, eliminating the need for a separate camera head, light cable and optical coupler. The Orangeburg, New York firm also claims that the products contain the world's smallest diameter insertion tube that incorporates a tiny high-resolution camera. The endoscopes can be used in conjunction with Vision-Sciences' Endosheath, which covers the entire device during examination in order to prevent the transfer of infection, and reduces the amount of high-level disinfection needed between procedures.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel